10-K: Alnylam Achieves First Profitability, Driven by AMVUTTRA Growth

Alnylam Pharmaceuticals reports its first profitable fiscal year in 2025, fueled by robust sales of AMVUTTRA and strategic pipeline advancements.

Summary

• Alnylam Pharmaceuticals achieved profitability for the first time in fiscal year 2025, reporting a net income of $313.7 million, a significant improvement from a net loss of $278.2 million in 2024.
• Total revenues increased by 65% to $3.71 billion in 2025, up from $2.25 billion in 2024.
• Net product revenues surged by 81% to $2.99 billion in 2025, primarily driven by AMVUTTRA sales, especially for ATTR amyloidosis with cardiomyopathy in the U.S.
• AMVUTTRA revenues in the United States grew by 175% to $1.73 billion in 2025, from $630.6 million in 2024.
• The company initiated Phase 3 clinical trials for nucresiran (TRITON-PN and TRITON-CM) and zilebesiran (ZENITH cardiovascular outcomes trial) in 2025.
• Alnylam's Alnylam 2030 strategy aims for global TTR leadership, 25%+ total revenue CAGR, ~30% non-GAAP operating margin, and 2+ new blockbuster medicines beyond TTR by 2030.
• Cash, cash equivalents, and marketable securities increased to $2.91 billion as of December 31, 2025, from $2.69 billion in 2024.
• The company repurchased approximately $672.2 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2027 for $1.11 billion, incurring an inducement expense of $42.5 million.
• Issued $661.3 million aggregate principal amount of 0.00% Convertible Senior Notes due 2028, with net proceeds used for the 2027 Notes repurchase and capped call transactions.
• Entered into a $500.0 million revolving credit facility, with no borrowings outstanding as of December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, reflecting Alnylam's successful transition to profitability, strong commercial growth driven by AMVUTTRA, and significant advancement of its late-stage pipeline, positioning the company well for its Alnylam 2030 strategic goals despite ongoing competitive and regulatory challenges.

Positives

• Achieved first-time annual profitability in fiscal year 2025 with a net income of $313.7 million.
• Experienced substantial total revenue growth of 65% to $3.71 billion in 2025.
• Net product revenues grew significantly by 81% to $2.99 billion, primarily from AMVUTTRA.
• AMVUTTRA received FDA approval for ATTR amyloidosis with cardiomyopathy in March 2025 and EC approval in June 2025, expanding its market.
• Positive Phase 1 results for nucresiran demonstrated rapid and sustained TTR knockdown of over 90% for six months, supporting less frequent dosing.
• Initiated two Phase 3 clinical trials for nucresiran (TRITON-PN and TRITON-CM) and a Phase 3 cardiovascular outcomes trial for zilebesiran (ZENITH) in 2025.
• Regeneron announced positive Phase 3 NIMBLE trial results for cemdisiran monotherapy in generalized myasthenia gravis, with a U.S. regulatory submission planned for Q1 2026.
• Leqvio received an expanded FDA indication in July 2025 for monotherapy use to reduce LDL-C, and is registered in 108 countries.
• Qfitlia received FDA approval in March 2025 and China NMPA approval in December 2025 for hemophilia A or B prophylaxis.
• Strong cash position with $2.91 billion in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Established a $500.0 million revolving credit facility, enhancing liquidity with no current borrowings.
• The company's Alnylam 2030 strategy outlines ambitious growth targets, including expanding to 10 tissue types and >40 clinical programs, and delivering 2+ new blockbuster medicines beyond TTR.

Negatives

• ONPATTRO revenues decreased by 32% to $172.8 million in 2025, primarily due to patients transitioning to AMVUTTRA.
• Cost of goods sold as a percentage of net product revenues increased to 22.7% in 2025 from 18.6% in 2024, mainly due to higher AMVUTTRA royalty rates.
• Interest expense increased by 78% to $252.6 million in 2025, partly due to the adoption of ASU 2025-07 and increased development funding liabilities.
• Incurred a $42.5 million loss related to convertible debt due to inducement expense from the partial repurchase of 2027 Notes.
• A partial clinical hold remains in place for mivelsiran in the U.S. for higher or more frequent dosing regimens due to non-clinical toxicology findings.
• The U.S. Supreme Court's Loper Bright Enterprises v. Raimondo decision could lead to increased legal challenges to federal agency regulations, creating regulatory uncertainty.
• Received an untitled letter from the FDA in September 2025 regarding an allegedly false and misleading DTC television advertisement for AMVUTTRA, though a close-out letter was received in November 2025.
• The company is subject to a subpoena from the U.S. Attorney's Office for the District of Massachusetts regarding government price reporting for its commercial products, which will incur significant expense and management attention.

Risks

• Inability to sustain and grow revenues from AMVUTTRA sales, which could be materially harmed by factors like safety/efficacy, reimbursement policies, competition, or manufacturing issues.
• Unsuccessful or less successful than anticipated marketing and sale of approved products, including AMVUTTRA for ATTR amyloidosis with cardiomyopathy.
• Inability to sustain profitability or positive cash flow from operations, despite achieving profitability in 2025, due to substantial ongoing R&D and commercialization costs.
• Requirement for substantial additional funds for R&D and commercialization activities, potentially leading to limiting or scaling back activities if funds are insufficient.
• Adverse impact on retained Leqvio royalties if sales are lower than expected, potentially triggering an increase in Blackstone Royalties' interest to 55% if $1.00 billion is not reached by December 31, 2029.
• Inaccuracy of estimates and assumptions in financial statements and projected guidance, leading to actual results varying from projections.
• Losses in the fair value of investments due to general credit, liquidity, market, and interest rate risks.
• Volatility in foreign currency exchange rates, particularly Japanese yen, Euro, and British pound, which could adversely affect operating results.
• Adverse effects on business, prospects, operating results, and financial condition due to changes in tax laws or additional tax liabilities.
• Inability to maintain existing or enter into new collaborations, impacting development and commercialization of product candidates.
• Delays or termination of product development and commercialization if collaborators amend, terminate, or fail to perform obligations.
• Significant costs and reliance on third parties for manufacturing, with risks of supply disruptions, delays, or inability to meet regulatory requirements.
• Adverse effects on development plans if third parties fail to conduct clinical trials adequately or on schedule.
• Inability to attract and retain qualified key management and staff, impacting business plan implementation.
• Difficulties in expanding global operations successfully at the necessary scale.
• Risks and challenges associated with social media use, including noncompliance with regulations, adverse impact on trial enrollment, and reputational harm.
• System failures or unauthorized access to information technology systems, leading to data loss, operational interruptions, and potential legal liabilities.
• Failure of product candidates in development or significant delays in clinical trials, due to factors like negative results, enrollment issues, or regulatory holds.
• Undesirable side effects or unexpected adverse properties of products or product candidates, potentially delaying or preventing regulatory approval or limiting commercial potential.
• Inability to obtain U.S. or foreign regulatory approval for product candidates, preventing commercialization.
• Ongoing regulatory oversight and potential penalties if compliance with U.S. and foreign requirements is not maintained.
• Significant liability if enforcement authorities allege or determine engagement in commercial activities with unapproved products or off-label promotion.
• Market not being receptive to product candidates upon commercial introduction, due to factors like safety, efficacy, convenience, pricing, or competition.
• Inability to continue developing and scaling global marketing, sales, market access, and distribution capabilities.
• Inaccurate estimates of patient populations, impacting commercial success.
• Unfavorable pricing regulations or healthcare reform initiatives, harming business and profitability.
• Substantial risk of product liability claims, potentially not fully covered by insurance.
• Employee misconduct or improper activities, leading to significant harm to business and financial condition.
• Failure to comply with environmental, health, and human safety laws, resulting in substantial costs or penalties.
• Inability to obtain and enforce patent protection for discoveries, harming ability to develop and commercialize products.
• Harm to competitive position if licensors do not properly obtain, maintain, or enforce licensed patents.
• Challenges to patent rights or assertion of patent rights by other companies, leading to substantial costs or cessation of development/commercialization efforts.
• Loss of license or other rights if obligations under licenses or related agreements are not complied with.
• Disclosure of trade secrets and proprietary information despite confidentiality agreements.
• Intense competition in the pharmaceutical market from existing drugs, new treatment methods, and new technologies.
• Competition from companies developing similar RNAi technology or more effective delivery technologies.
• Volatility in stock price due to various factors, including financial results, regulatory actions, competition, and economic conditions.
• Inability to have sufficient cash flow to pay indebtedness, including convertible notes, or to repurchase notes upon a fundamental change.
• Adverse effects on liquidity if the conditional conversion feature of the notes is triggered.
• Dilution of ownership interests of existing stockholders upon conversion of notes.
• Counterparty risk with respect to capped call transactions.
• Lack of regular interest on 2028 Notes, meaning holders may not earn a return unless resold at a higher price or converted for a gain.
• Material effect on reported financial results due to accounting method for convertible debt securities, potentially reducing diluted EPS or reclassifying debt as current liability.

Future Outlook

The company expects to fund operations primarily from product revenues, supplemented by collaboration and royalty revenues. Research and development expenses, combined with selling, general and administrative expenses, are projected to increase in 2026 due to new market launches, advancement of product candidates into later-stage development, platform and preclinical pipeline development, and regulatory submissions. Royalty revenue is expected to increase in 2026 due to continued growth of Leqvio sales, while net revenues from collaborations are expected to decrease due to a large milestone recognized in 2025. The company anticipates sufficient liquidity for at least the next 12 months based on current operating plans and expected revenues.

Management Comments

• We launched our Alnylam 2030 strategy to drive the Company's next era of growth and patient impact, aspiring to achieve global TTR leadership, deliver 2+ new transformative medicines beyond TTR with blockbuster potential, expand to 10 tissue types and >40 clinical programs, and achieve 25%+ total revenue CAGR with ~30% non-GAAP operating margin through year-end 2030.
• Our launch strategy in the U.S. for AMVUTTRA in ATTR-CM is based on three core pillars: health system set-up, access, and treatment choice.
• We believe that with its anticipated product profile, nucresiran has the potential to become a leading therapy for ATTR amyloidosis and to significantly improve our gross margins on product sales and our non-GAAP operating income margin.
• We intend to grow through continued scientific innovation rather than more substantial price increases, and will not raise the price of any product for which we receive marketing approval over the rate of inflation, absent a significant value driver.

Industry Context

StockSavvy.ai notes that Alnylam's achievement of its first profitable year is a significant milestone in the RNAi therapeutic space, demonstrating the increasing maturity and commercial viability of this innovative drug class. The strong performance of AMVUTTRA, particularly in the ATTR-CM market, positions Alnylam as a leader in rare disease treatments, while its expansion into prevalent diseases like hypertension with zilebesiran reflects a broader industry trend of leveraging advanced therapeutic platforms for wider market applications. The competitive landscape, especially in ATTR amyloidosis and hypercholesterolemia, remains intense with multiple approved therapies and late-stage candidates, underscoring the importance of Alnylam's continued innovation and strategic collaborations to maintain market share and drive future growth. The ongoing regulatory scrutiny on drug pricing and the evolving landscape of data privacy and cybersecurity are industry-wide challenges that Alnylam, like its peers, must navigate effectively.

Comparison to Industry Standards

• In the ATTR amyloidosis market, AMVUTTRA competes with Pfizer's VYNDAQEL/VYNDAMAX and BridgeBio's ATTRUBY (Beyonttra by Bayer/Alexion in Europe/Japan), both oral therapies. While AMVUTTRA is subcutaneously administered, its competitive profile is strong, but the lower list prices of oral competitors could impact market share.
• For hATTR-PN, AMVUTTRA and ONPATTRO compete with Ionis and AstraZeneca's WAINUA (eplontersen) and Ionis's TEGSEDI (inotersen, not available in the U.S.). The transition of patients from ONPATTRO to AMVUTTRA indicates a preference for the newer, subcutaneously administered therapy.
• In Primary Hyperoxaluria Type 1 (PH1), OXLUMO competes with Novo Nordisk's RIVFLOZA (nedosiran), another once-monthly subcutaneous RNAi therapy. Both offer significant advancements over traditional management options like hyperhydration and vitamin B6, and dual liver/kidney transplant.
• In hypercholesterolemia, Leqvio (Novartis) competes with established PCSK9 inhibitors like Amgen's REPATHA and Sanofi's PRALUENT, as well as newer approvals like LIB Therapeutics' LEROCHOL and Jiangsu Hengrui Pharmaceuticals' recaticimab. Leqvio's expanded monotherapy indication strengthens its competitive position.
• For hemophilia, Qfitlia (Sanofi) enters a market with existing Factor VIII/IX replacement products, extended half-life products, anti-TFPI products, and bispecific antibodies. BioMarin's ROCTAVIAN gene therapy also represents a significant competitive factor.
• In hypertension, zilebesiran faces a crowded market with various approved treatments (ACE inhibitors, ARBs, calcium channel blockers, diuretics, beta blockers, mineralocorticoid receptor antagonists, Idorsia's Tryvio) and emerging classes like aldosterone synthase inhibitors (AstraZeneca, Mineralys Therapeutics). Its long-acting RNAi mechanism aims to differentiate it from daily oral medications.
• For complement-mediated diseases like myasthenia gravis, cemdisiran (Regeneron) competes with C5 inhibitors (Alexion's SOLIRIS, ULTOMIRIS; UCB's ZILBRYSQ) and neonatal Fc receptor inhibitors (argenx's VYVGART, UCB's RYSTIGGO, J&J's IMAAVY), as well as Amgen's CD19-targeted UPLIZNA. Positive Phase 3 results suggest a strong competitive entry.

Management Changes

Corporate Governance

Legal Proceedings

• In December 2024, The Board of Regents of the University of Texas System filed a lawsuit alleging infringement of U.S. Patent No. 8,895,717 by ONPATTRO in the U.S. The case was transferred to the U.S. District Court for the District of Massachusetts in December 2025.
• In July 2024, Acuitas Therapeutics Inc. filed a declaratory judgment action against Alnylam, seeking to add certain Acuitas employees as co-inventors on patents asserted against Pfizer/BioNTech and Moderna. Alnylam's motion to dismiss was granted without prejudice in July 2025, finding Acuitas lacked standing.
• In October 2025, Alnylam received a subpoena from the U.S. Attorney's Office for the District of Massachusetts seeking documents related to government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI, including fee and discount arrangements with distributors. The company is producing responsive records, anticipating significant expense and management attention.
• Alnylam filed separate lawsuits in March 2022 against Moderna and Pfizer for patent infringement related to their mRNA COVID-19 vaccines. Both lawsuits were settled in August and September 2025, respectively.

Related Party Transactions

• In April 2020, Alnylam sold 50% of royalties and 75% of commercial milestones payable from Novartis's sales of Leqvio to BX Bodyguard Royalties L.P. (an affiliate of The Blackstone Group Inc.) for $1.00 billion. If Blackstone Royalties does not receive $1.00 billion by December 31, 2029, its interest increases to 55%.
• In August 2020, Alnylam entered into a co-development agreement with Blackstone Life Sciences (an affiliate of The Blackstone Group Inc.) for up to $150.0 million in funding for vutrisiran and zilebesiran development. As of December 31, 2025, Blackstone Life Sciences provided $70.0 million for vutrisiran and $26.0 million for zilebesiran Phase 2, with an additional $6.0 million provided for zilebesiran Phase 3. Alnylam owes Blackstone Life Sciences $175.0 million upon vutrisiran ATTR-CM approval (triggered March 2025) and a 1% royalty on vutrisiran net sales for 10 years, plus $84.5 million for zilebesiran Phase 2 milestone (triggered September 2023) and $243.0 million for zilebesiran Phase 3 regulatory approval.

Stakeholder Impact

• **Shareholders:** Positive impact from the company achieving its first profitable year, strong revenue growth, and advancement of a robust pipeline. However, potential dilution from convertible notes and stock price volatility remain risks.
• **Patients:** Expanded access to AMVUTTRA for ATTR-CM and continued development of therapies for rare and prevalent diseases (nucresiran, zilebesiran, mivelsiran, ALN-6400, ALN-HTT02) offer new treatment options and improved outcomes. Patient support programs aim to enhance affordability and access.
• **Employees:** Continued growth in headcount and investment in R&D and commercial capabilities provide employment opportunities and professional development. Equity compensation and competitive total rewards packages are designed for attraction and retention.
• **Collaborators (Roche, Regeneron, Sanofi, Novartis, Vir, PeptiDream):** Continued successful collaborations and milestone achievements benefit all parties. Regeneron's opt-out from mivelsiran development shifts funding responsibility to Alnylam but allows Alnylam full rights. Novartis's Leqvio sales growth drives royalty revenue for Alnylam and Blackstone. Vir's progress with elebsiran also generates milestones and royalties.
• **Creditors (Convertible Note Holders, Revolving Credit Facility Lenders):** The company's improved profitability and strong cash position enhance its ability to service debt obligations. Repurchase of 2027 Notes and issuance of 2028 Notes demonstrate active capital management.
• **Suppliers/CMOs:** Continued reliance on third-party CMOs for manufacturing, with planned expansion of internal facilities, indicates ongoing business for these partners. The BIOSECURE ACT could impact relationships with Chinese biotechnology companies.

Next Steps

• Continue global regulatory filings and product launches for AMVUTTRA in additional countries for ATTR amyloidosis with cardiomyopathy.
• Advance nucresiran through Phase 3 clinical trials (TRITON-PN and TRITON-CM) for hATTR polyneuropathy and ATTR amyloidosis with cardiomyopathy.
• Continue the ZENITH Phase 3 cardiovascular outcomes clinical trial for zilebesiran in uncontrolled hypertension.
• Initiate a Phase 2 clinical trial of mivelsiran in patients with Alzheimer's disease in the first half of 2026.
• Present initial data from the ALN-HTT02 Phase 1b clinical trial in Huntington's disease in the second half of 2026.
• Share additional data from the ALN-6400 Phase 1 clinical trial and report clinical proof of concept in HHT in the second half of 2026.
• Initiate a Phase 2 clinical trial for ALN-6400 in a second bleeding disorder in the first half of 2026.
• File three or more new investigational new drug applications (INDs) or CTAs from the organic product engine during 2026.
• Continue to build on progress with extrahepatic delivery initiatives, including CNS programs under collaboration with Regeneron, to expand to ten tissue types by 2030.
• Regeneron plans a U.S. regulatory submission for cemdisiran monotherapy in the first quarter of 2026.
• Vir expects topline data from the ECLIPSE 1 Phase 3 clinical trial of elebsiran in CHD in the fourth quarter of 2026.
• Vir expects topline data from the ECLIPSE 2 and 3 clinical trials of elebsiran in the first quarter of 2027.
• Continue to scale global commercial organization and infrastructure to support planned expansion to commercialize RNAi therapeutics in prevalent diseases.

Key Dates

Recommendation

Alnylam's achievement of its first profitable year, coupled with significant revenue growth driven by AMVUTTRA's expanded indications, signals a strong commercial trajectory. The robust late-stage pipeline, including nucresiran and zilebesiran, offers substantial future growth potential, particularly with the absence of royalties on nucresiran. Strategic collaborations continue to de-risk development and expand market reach. While competitive pressures and regulatory scrutiny exist, the company's strong financial position, disciplined investment in innovation, and clear Alnylam 2030 strategy make it a compelling 'strong buy' for long-term investors.

Keywords

RNAi therapeutics, Biopharmaceutical, ATTR amyloidosis, Cardiomyopathy, Polyneuropathy, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio, Qfitlia, Nucresiran, Zilebesiran, Hypertension, Cerebral Amyloid Angiopathy, Alzheimer's Disease, Hemophilia, Acute Hepatic Porphyria, Primary Hyperoxaluria, Clinical trials, Regulatory approval, Commercialization, Financial performance, SEC filing, 10-K, Biotechnology, Drug development, Orphan drug, Patent litigation, Convertible notes, Capital raise, Profitability